Lexaria Bioscience strikes R&D agreement with Brit
Post# of 721
The company said Peter Diatelevi has been appointed as Boldt Runners' new chief executive officer. He brings more than two decades of experience with Altria Corp, leading field sales and sales operations in a number of roles including vice president of sales operations.
Also, Maura Scott has been appointed chief sales and compliance officer, and was most recently vice president of the Northeast Region and led a sales team of 400 people across 13 states for Altria Corp. And Case Mandel, former Boldt Runners CEO and co-founder, is now chairman of the board and president.
"I am excited to join the Cannadips CBD brand and am truly fortunate to be working with such an amazing team and product,” said Diatelevi in a statement.
“I have long believed that providing a viable non-tobacco and non-nicotine dip alternative for adults is an important step forward. The work Cannadips CBD has done on the development of this product is outstanding, and I look forward to working with Lexaria as we continue to develop and implement the technology."
Fostering growth in sales and manufacturing
Lexaria said Boldt Runners is fostering growth in sales and manufacturing. The company recently built a new state-of-the-art manufacturing facility in Humboldt County, California, that will allow for expanded production levels of cutting-edge pouching technologies, as well as for future growth. In addition, the licensed facility will soon include the capability of implementing Lexaria's DehydraTECH technologies into infused cannabinoid products.
Cannadips CBD plans continued expansion through its existing relationship with existing and future trade partners and with a strong e-commerce presence, will be introducing new flavors throughout these networks, including planned expansions to new states.
The Kelowna, British Columbia-based Lexaria has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.
https://www.proactiveinvestors.com/companies/...29232.html
Think about this folks, Boldt Runners is a licensee of Lexaria Bioscience and Altria Corp. is investing in Lexaria. Now, we find that the new CEO of Boldt Runners (Peter Diatelevi) formerly was the vice president of sales operations at Altria. Maura Scott who was recently appointed Boldt Runners chief sales and compliance officer is also formerly from Altria. This sounds like a pretty firm relationship to big tobacco to me.